BioCytoGen (CEO Yuelei Shen) participated in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereinafter referred to as Biocytogen) is a global biotechnology company that researches and develops antibody-based medicines with innovative technologies. Proprietary experimental mouse platforms RenMab, RenLite and RenNano for the development of fully human monoclonal, bispecific, multispecific and nanoantibodies, combined with our in vivo drug trial platform and powerful An official explained that all procedures of new drug development were simplified by utilizing expertise in clinical development.
Currently, a large-scale Project Integrum is underway to develop innovative (FIC) and excellent (BIC) antibody drugs that achieve more than 1 targets. In addition, it has signed 34 new drug joint development agreements and 17 RenMice licensing agreements with companies around the world. BioCytogen’s pipeline includes 11 core assets, and partnerships have been established for four out of a total of six clinical assets. Headquarters are located in Beijing, China, with offices in Haimen, Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.
BioCytogen provides gene editing services, genetically modified animal and cell models (primarily humanized) and murine models of immunodeficiency, and preclinical pharmacology services through the BioMice brand. Monoclonal antibodies, bispecific antibodies, nanoantibodies, bispecific antibody drug conjugates (ADCs), T cell receptor embodying antibodies, protein-coupled receptor (GPCR) targeting antibodies, Renmice licensed platform specialized in the discovery of fully human antibodies, and Antibody-based molecules for therapeutic purposes, which are difficult to license, jointly develop, and transfer, are also touted.
The Renmais, Renmab, Renlite, and Rennano lab mice were developed with Unlimited Scale Fine Chromosome Engineering (SUPCE) technology over a period of five years, all with registered intellectual property rights. Renmais is among the world’s top three mice with human antibodies made with in situ replacement technology, the company said. All Renmais individuals carry fully human heavy chain genes with the VDJ coordinates replaced in situ.
It was also emphasized that Renmais can generate a strong immune response and generate fully human antibodies with excellent diversity, specificity, affinity and pharmacological properties. Leveraging Renmais, Biocytogen has developed six fully human antibody discovery platforms that address a variety of targets and modalities.
BioCytogen has entered into partnerships with 10 of the top 9 multinational companies in the BioMice industry. So far, the number of gene editing projects contributed by customers has exceeded 3,500, and the number of self-developed gene editing animal and cell models sold in more than 20 countries has exceeded 2,800. The number of completed pharmacology programs provided to customers has exceeded 1,900.
BioCytogen said, “We plan to expand our customer base and business around the world in the future. To help companies evaluate new drugs, gene-edited animal and cell models for new targets are being developed. We are developing new disease models such as metabolic and autoimmune diseases to meet the demand,” he said. It is expected to produce all kinds of fully human antibody arrays.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.